Image Plus Consultants Limited FY ENDED FEB 28 2025 Earnings Call Summary

Image Plus Consultants Limited (IPCL), a recognized leader in advanced radiology services, hosted its Q3 2025 Earnings Call on January 22, 2025, presented by Learn Grow Invest. CEO Kisha Anderson delivered a detailed review of the financial results for the quarter, emphasizing key strategic initiatives and performance improvements. The presentation highlighted the company’s commitment to innovation, market expansion, and operational efficiency, providing valuable insights into its performance and future direction as it navigates challenges and drives forward its growth plans.

Presentation Highlights

Net Profit Performance

For Q3 2025, Image Plus Consultants Limited (ICPL) reported a net profit of $26.2 million. While this represents a 57% decrease compared to the same period last year, it reflects a sequential improvement relative to Q2 2025 results. Year-to-date, the company has generated a net profit of $41.6 million, marking a 75% decline from the prior year. Ms. Anderson noted that while overall net profit has been negatively impacted, the recent quarter’s results show signs of stabilization and an improvement compared to Q2.

Revenue Review

Revenue for Q3 2025 totaled $547.8 million, reflecting a 5.9% decrease compared to the prior year. However, this represents a slight improvement over the company’s Q2 2025 revenue performance. Year-to-date, total revenue has declined by 1.7%, which Mrs. Anderson attributed to a reduction in scan volumes, particularly in the key areas of X-rays and CT scans. Despite these challenges, the company is optimistic about the trajectory moving forward, as certain modalities have shown growth, particularly mammography and MRI services.

Gross Profit Margin and Expense Management

Mrs. Anderson highlighted that the company is keenly aware of the primary cost drivers affecting its profitability, including the acquisition of new imaging equipment, depreciation, loan servicing costs, salaries, and utility expenses. She emphasized that the company has been actively working to streamline these costs and improve operational efficiency, with improvements expected on a quarter-over-quarter basis.

Scan Volume and Revenue Streams

The reduction in scan volumes has been a significant factor impacting revenue, with particular emphasis on the decline in CT scan procedures. CT scans, which were a major revenue contributor in the previous year, showed a notable decline, which had a material effect on year-to-date figures. However, Mrs. Anderson pointed to the growth in the volume of mammograms and MRIs, which are being developed as new revenue streams for the company.

Notably, mammograms and MRI scans now represent 9% of the total scan count, and the company views these modalities as key drivers for future growth. Management has identified these areas as crucial lead indicators, and they plan to continue focusing on expanding these services.

Other lead indicators include growth in scan count by source. During the Q3 2025 earnings call, CEO Kisha Anderson addressed the Ministry of Health and Wellness (MOHW) issuing procurement to acquire its own MRI and CT scan machines. While this development didn’t impact Q3 results, IPCL expects effects in Q4, as patients who were previously referred to private entities may now turn to public options. While short-term demand may dip, the company anticipates stabilization as the market adjusts. Additionally, potential downtime of public machines could maintain a need for private partnerships.

To manage this, IPCL is focused on fostering growth to offset any drop in referrals. In response to delayed payments from the MOHW, the company has decided to sell $75.8 million in receivables to improve cash flow and enhance financial flexibility.

Outlook

Mrs. Anderson also addressed the company’s inorganic growth opportunities, noting that while they are making significant progress, they are not yet ready to disclose specific details. She emphasized that due diligence is ongoing, with a substantial update expected at the company’s Annual General Meeting. Regarding the 33LMR Joint Venture, Mrs. Anderson shared that all agreements are anticipated to be signed within the next week or two, after which the necessary disclosures will be made to regulators and the public. She expressed confidence that these developments will drive positive change, positioning the company for long-term, sustainable growth and ensuring returns for shareholders.

In summary, while Q3 2025 presented some challenges in revenue and net profit, the company remains optimistic. With positive momentum in key areas and ongoing efforts to manage expenses and improve operations, the success of new services like mammograms and MRIs will be crucial to the company’s performance in the upcoming quarters.

Q3 Activities

Mrs. Anderson then highlighted ICPL’s Q3 activities, focusing on team engagement and outreach efforts aimed at building brand presence and reinforcing their commitment to corporate social responsibility. The company participated in several Pink Runs during October for Breast Cancer Awareness Month, leveraging the opportunity to promote their new mammogram services. The team engaged with potential patients, raising awareness of the offering and even providing gift certificates for scans. Additionally, ICPL continued to sponsor health-related events, such as the shirt sponsorship for the UWI Radiographers Society and presented at various conferences. Mrs. Anderson also encouraged shareholders to suggest any relevant outreach activities they would like the company to support.

Key Takeaways from Q&A Session

Following the presentation, the company’s management team addressed a variety of investor questions, providing additional context for its strategy and outlook:

• Growth Strategy: Management outlined plans to diversify its services further, with a particular emphasis on leveraging tele-radiology to expand access to diagnostic services in underserved regions. This initiative is expected to drive growth and improve healthcare accessibility.
• Financial Outlook: Mrs. Anderson also discussed the company’s financial outlook, expressing optimism about its future trajectory. She highlighted continued demand for IPCL’s services and ongoing operational improvements as key drivers of sustained performance. The leadership team anticipates maintaining strong financial results, supported by favorable market conditions. Additionally, Mrs. Anderson mentioned that the company would be open to exploring potential capital-raising opportunities to further strengthen its position and support future growth initiatives. This could provide the necessary resources for strategic investments and continued expansion.
• Regulatory Preparedness: In response to investor concerns about evolving regulatory environments, Image Plus Consultants reassured stakeholders of their proactive approach. The company is fully prepared to comply with any new regulations, safeguarding its operations and business continuity.
• Technological Integration: The integration of artificial intelligence (AI) into diagnostic workflows is a top priority for Image Plus. Management highlighted the potential of AI to improve diagnostic accuracy and reduce turnaround times, enhancing both the patient’s experience and operational efficiencies.

Conclusion

Image Plus Consultants Limited’s Q3 2025 earnings call underscored a company positioned for sustained success. With a clear strategy centered around innovation, market expansion, and operational excellence, the company is primed for continued growth. The strong financial results, combined with a commitment to sustainability and cutting-edge technologies, signal a bright future for Image Plus Consultants and their shareholders.

Investors are encouraged to review the full earnings call for deeper insights into the company’s performance, strategic goals, and prospects. The recording of the earnings call is available for those interested in exploring the discussion further.